Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Quick facts
Phase 3 pipeline
- BMS-986353 · Oncology
BMS-986353 is a CAR-T cell therapy that redirects patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen. - BMS-986393 · Oncology
BMS-986393 is a CAR-T cell therapy that redirects patient T cells to recognize and kill cancer cells expressing the CD19 antigen. - Liso-cel · Oncology
Liso-cel is a CAR-T cell therapy that redirects a patient's own T cells to recognize and kill B cells expressing CD19.
Phase 2 pipeline
- CC-97540 · Oncology
CC-97540 is a monoclonal antibody targeting CD47.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: